You just read:

Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

News provided by

Merck KGaA

Sep 11, 2019, 02:30 ET